MX2021004769A - Compuestos, composiciones, y metodos para modular la actividad cdk9. - Google Patents

Compuestos, composiciones, y metodos para modular la actividad cdk9.

Info

Publication number
MX2021004769A
MX2021004769A MX2021004769A MX2021004769A MX2021004769A MX 2021004769 A MX2021004769 A MX 2021004769A MX 2021004769 A MX2021004769 A MX 2021004769A MX 2021004769 A MX2021004769 A MX 2021004769A MX 2021004769 A MX2021004769 A MX 2021004769A
Authority
MX
Mexico
Prior art keywords
modulating
compositions
compounds
methods
cdk9 activity
Prior art date
Application number
MX2021004769A
Other languages
English (en)
Spanish (es)
Inventor
Peter Mikochik
David Freeman
Joseph VACCA
Andrew Tasker
Original Assignee
Kronos Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc
Publication of MX2021004769A publication Critical patent/MX2021004769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021004769A 2018-10-30 2019-10-29 Compuestos, composiciones, y metodos para modular la actividad cdk9. MX2021004769A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
MX2021004769A true MX2021004769A (es) 2021-08-24

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004769A MX2021004769A (es) 2018-10-30 2019-10-29 Compuestos, composiciones, y metodos para modular la actividad cdk9.

Country Status (21)

Country Link
US (3) US11155560B2 (cg-RX-API-DMAC7.html)
EP (2) EP3873911A4 (cg-RX-API-DMAC7.html)
JP (1) JP7385658B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250174699A (cg-RX-API-DMAC7.html)
CN (1) CN112996790B (cg-RX-API-DMAC7.html)
AU (1) AU2019370200B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008176A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118472A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005502A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210202A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000066A (cg-RX-API-DMAC7.html)
IL (1) IL282254B2 (cg-RX-API-DMAC7.html)
MA (1) MA54092A (cg-RX-API-DMAC7.html)
MD (1) MD20210033A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004769A (cg-RX-API-DMAC7.html)
MY (1) MY210039A (cg-RX-API-DMAC7.html)
PE (1) PE20212196A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550857A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104229WA (cg-RX-API-DMAC7.html)
WO (1) WO2020092314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102609B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
WO2022098843A1 (en) * 2020-11-05 2022-05-12 Kronos Bio, Inc. Compounds and methods for modulating cdk9 activity
AU2022211514B2 (en) * 2021-01-22 2024-06-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
EP4436569A4 (en) * 2021-11-24 2025-10-01 Kronos Bio Inc POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
WO2024017365A1 (zh) * 2022-07-22 2024-01-25 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用
WO2025153034A1 (zh) * 2024-01-19 2025-07-24 上海海雁医药科技有限公司 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
EP0714898B1 (en) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd 5−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
WO2003095455A2 (en) 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4881558B2 (ja) * 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US20070293511A1 (en) 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
CA2576949A1 (en) * 2004-08-13 2006-02-16 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivatives
CN101119998A (zh) 2004-12-21 2008-02-06 先灵公司 吡唑并[1,5-A]嘧啶腺苷A2a受体拮抗剂
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
EP1931675B1 (en) 2005-10-06 2015-01-14 Merck Sharp & Dohme Corp. Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2027127A1 (en) 2006-05-22 2009-02-25 Shering Corporation Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
CA2691932A1 (en) 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
PH12012501643A1 (en) 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
WO2011108689A1 (ja) 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012044562A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2802588B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
SG11201507629XA (en) * 2013-03-15 2015-10-29 Human Biomolecular Res Inst Compounds and matrices for use in bone growth and repair
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016169995A1 (en) 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
ES2767776T3 (es) 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
WO2017180499A2 (en) 2016-04-13 2017-10-19 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법

Also Published As

Publication number Publication date
KR20210068597A (ko) 2021-06-09
EP4775584A1 (en) 2026-07-15
MA54092A (fr) 2021-09-08
US11155560B2 (en) 2021-10-26
PE20212196A1 (es) 2021-11-16
JP2022505268A (ja) 2022-01-14
US20240132506A1 (en) 2024-04-25
IL282254B2 (en) 2025-08-01
DOP2021000066A (es) 2021-10-31
CA3118472A1 (en) 2020-05-07
CR20210202A (es) 2022-02-08
IL282254B1 (en) 2025-04-01
PH12021550857A1 (en) 2021-12-06
KR20250174699A (ko) 2025-12-12
MY210039A (en) 2025-08-22
US11845754B2 (en) 2023-12-19
IL282254A (en) 2021-05-31
AU2019370200A1 (en) 2021-06-10
CN112996790A (zh) 2021-06-18
EP3873911A4 (en) 2022-06-22
BR112021008176A2 (pt) 2021-08-03
CO2021005502A2 (es) 2021-09-20
CN112996790B (zh) 2023-11-03
WO2020092314A1 (en) 2020-05-07
ZA202102609B (en) 2023-02-22
AU2019370200B2 (en) 2024-12-19
US20220002305A1 (en) 2022-01-06
SG11202104229WA (en) 2021-05-28
EP3873911A1 (en) 2021-09-08
JP7385658B2 (ja) 2023-11-22
US20200131189A1 (en) 2020-04-30
MD20210033A2 (ro) 2021-10-31

Similar Documents

Publication Publication Date Title
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
EA201690752A1 (ru) Ингибиторы g12c kras
PH12021550019A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
MX2022008103A (es) Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
EA201991884A3 (ru) Ингибиторы g12c kras
GEAP202215630A (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2024001202A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
GEAP202415849A (en) Crystalline salt forms of kinase inhibitor
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida